Recent Publications by UCB S.A: |
Visualization of SV2A conformations in situ by the use of Protein Tomography.
The synaptic vesicle protein 2A (SV2A), the brain-binding site of the... | 28th October, 2008
| Department of Molecular and Cellular Sciences, UCB S.A., Granta Park,
| Biochem Biophys Res Commun. 2008 Oct 31;375(4):491-5. Epub 2008 Aug 8.
DOI Direct Link |
2,6-Quinolinyl derivatives as potent VLA-4 antagonists.
A new series of 2,6-quinolinyl derivatives was prepared leading to potent... | 25th April, 2007
| UCB S.A., R&D, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium.
| Bioorg Med Chem Lett. 2007 Jan 1;17(1):142-6. Epub 2006 Oct 10.
DOI Direct Link |
Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: identification of a lead and initial SAR studies.
High-throughput screening of the UCB sample collection identified the... | 25th April, 2007
| CNS Molecular and Cellular Biology, Centre for CNS Innovation, UCB S.A.,
| Bioorg Med Chem Lett. 2007 Jan 1;17(1):272-7. Epub 2006 Oct 5.
DOI Direct Link |
The connexin 36 blockers quinine, quinidine and mefloquine inhibit cortical spreading depression in a rat neocortical slice model in vitro.
A protocol for inducing cortical spreading depression (SD) on rat... | 3rd February, 2007
| UCB S.A., CNS Research, B-1420 Braine-l'Alleud, Belgium.
| Brain Res Bull. 2006 Dec 11;71(1-3):23-8. Epub 2006 Aug 11.
DOI Direct Link |
Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
A specific binding site for the antiepileptic drug levetiracetam... | 26th July, 2006
| UCB S.A., CNS Research, Chemin du Foriest, 1420 Braine L'Alleud, Belgium.
| Eur J Pharmacol. 2006 Apr 24;536(1-2):102-8. Epub 2006 Mar 10.
DOI Direct Link |
Differential effects of cation-chloride co-transport-blocking diuretics in a rat hippocampal slice model of epilepsy.
The cation-Cl- co-transport-blocking loop diuretics have clinically known... | 13th July, 2006
| UCB S.A., CNS Research, B-1420 Braine-l'Alleud, Belgium.
| Epilepsy Res. 2006 May;69(2):93-9. Epub 2006 Feb 21.
DOI Direct Link |
Solubilization and immunopurification of rat brain synaptic vesicle protein 2A with maintained binding properties.
This study reports the solubilization of the rat synaptic vesicle protein... | 11th May, 2006
| UCB S.A., CNS In Vitro Pharmacology, Building R4, Chemin du Foriest,
| Neurosci Lett. 2006 May 1;398(1-2):107-12. Epub 2006 Jan 24.
DOI Direct Link |
Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction.
RATIONALE: The aim of this review article is to analyse which... | 5th May, 2006
| Drug Metabolism and Pharmacokinetics, UCB S.A., 21 rue de Neuilly, 92003
| Eur J Clin Pharmacol. 2005 Dec;61(12):863-72. Epub 2005 Nov 24.
DOI Direct Link |
Changes in pH differently affect the binding properties of histamine H1 receptor antagonists.
We investigated the effect of acidic pH, a condition that can be... | 11th March, 2006
| UCB S.A., In vitro Pharmacology, Building R4, Chemin du Foriest, 1420
| Eur J Pharmacol. 2006 Jan 20;530(3):205-14. Epub 2006 Jan 4.
DOI Direct Link |
Characterization of [(3)H]ucb 30889 binding to synaptic vesicle protein 2A in the rat spinal cord.
The novel antiepileptic drug levetiracetam... | 14th February, 2006
| UCB S.A., CNS In Vitro Pharmacology, Building R4, Chemin du Foriest,
| Eur J Pharmacol. 2005 Sep 27;520(1-3):70-6.
DOI Direct Link |
Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines.
The predictive efficacy of drugs in humans is frequently estimated from... | 13th December, 2005
| UCB S.A., In Vitro Pharmacology Department, Chemin du Foriest, UCB S.A.,
| Inflamm Res. 2005 Sep;54(9):367-9.
DOI Direct Link |
Caffeine-induced epileptiform field potentials in rat hippocampal slices: a pharmacological characterization.
Pharmacological modulation of the epileptiform electric activity induced... | 14th January, 2005
| Preclinical CNS Research, UCB S.A. Pharma Sector, Chemin du Foriest,
| Neuropharmacology. 2004 Nov;47(6):926-34.
DOI Direct Link |
Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog.
1: The pharmacokinetics and metabolism of 14C-levetiracetam, a new... | 13th November, 2004
| UCB S. A., Pharma Sector, Department of Global Product Safety and
| Xenobiotica. 2004 Mar;34(3):281-300.
DOI Direct Link |
Is the persistent sodium current a specific target of anti-absence drugs?
The persistent Na+ current (INaP) has been proposed as the putative target... | 30th June, 2004
| UCB S.A. Pharma Sector, Preclinical CNS Research, Chemin du Foriest,
| Neuroreport. 2004 Apr 29;15(6):1049-52.
|
Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.
(S)-alpha-ethyl-2-oxopyrrolidine acetamide 2 (levetiracetam, Keppra, UCB... | 23rd March, 2004
| Chemical Research, Preclinical CNS Research, and In Vitro Pharmacology,
| J Med Chem. 2004 Jan 29;47(3):530-49.
DOI Direct Link |
